Literature DB >> 2510730

The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme.

M W Coughtrie1, B Ask, A Rane, B Burchell, R Hume.   

Abstract

The formation of morphine glucuronides is enantio- and regioselective in rats and humans. In rat liver microsomes, natural (-)-morphine formed only the 3-O-glucuronide, whereas the unnatural (+)-morphine formed glucuronides at both the 3-OH and 6-OH positions, with the 6-O-glucuronide being the principal product. In human liver microsomes, both the 3-OH-and 6-OH positions were glucuronidated with each of the enantiomers, with the 3-O-glucuronide being the major product with (-)-morphine, and the 6-OH position preferred with the (+)-enantiomer. By using a series of biochemical and biological situations such as induction by xenobiotics, ontogeny, selective inhibition and genetic deficiencies, which are considered to be diagnostic of UDP-glucuronosyltransferase heterogeneity, we determined that two UDP-glucuronosyltransferase isoenzymes were responsible for the glucuronidation of morphine in rat liver. One isoenzyme (the so-called "morphine UDP-glucuronosyltransferase") was responsible for the glucoronidation at the (-)-3-OH and (+)-6-OH positions of morphine, whereas the other formed only the (+)-morphine-3-glucuronide. Evidence from enzyme induction and the genetically deficient deficient Gunn rat suggested that bilirubin UDPGT may be responsible for the (+)-morphine-3-UDP-glucuronosyltransferase activity. In human kidney, glucuronidation of both (-)- and (+)-enantiomers at the 6-OH position was deficient, whereas the activity at the 3-OH positions was still present, which indicated the involvement of two UDP-glucuronosyltransferases in the glucuronidation of morphine in man, as well as rats.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510730     DOI: 10.1016/0006-2952(89)90625-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 2.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model.

Authors:  Sebnem Atici; Ismail Cinel; Leyla Cinel; Nurcan Doruk; Gulcin Eskandari; Ugur Oral
Journal:  J Biosci       Date:  2005-03       Impact factor: 1.826

4.  Relationship between morphine analgesia and cortical extracellular fluid levels of morphine and its metabolites in the rat: a microdialysis study.

Authors:  M J Barjavel; J M Scherrmann; H N Bhargava
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

6.  Differential localisation of UDP-glucuronosyltransferase in kidney during human embryonic and fetal development.

Authors:  R Hume; M W Coughtrie; B Burchell
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

7.  Morphine sulphation in children.

Authors:  I Choonara; Y Ekbom; B Lindström; A Rane
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

8.  Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

Authors:  Glynn A Morrish; David J R Foster; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

Review 9.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose.

Authors:  T A Aasmundstad; B Q Xu; I Johansson; A Ripel; A Bjørneboe; A S Christophersen; E Bodd; J Mørland
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.